

April 7, 2022

To,
SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sirs,

Sub: Outcome of the Board Meeting held on 7th April, 2022

Pursuant to Regulation 30 of the SEBI LODR, Regulations 2015, we wish to inform you that, based on the recommendation of the Nomination and Remuneration Committee, Board at its meeting held today, has approved the following:

- a) Re-appointment of Mr. Glenn Saldanha (DIN- 00050607) as Chairman & Managing Director of the Company for a further period of 5 years with effect from 16th May, 2022; and
- b) Re-appointment of Mrs. Cherylan Pinto (DIN- 00111844) as an Executive Director – Corporate Services of the Company for a further period of 5 years with effect from 16th May, 2022.

Further, the Board of Directors have decided to seek the consent of the members of the Company by way of Resolution(s) through Postal Ballot Process for:

- a) Re-appointment of Mr. Glenn Saldanha as Chairman & Managing Director of the Company for a further period of 5 years with effect from 16th May, 2022; and
- b) Re-appointment of Mrs. Cherylan Pinto as an Executive Director – Corporate Services of the Company for a further period of 5 years with effect from 16th May, 2022.

The Board of Directors have appointed Mr. Surjan Singh Rauthan, Practicing Company Secretary, who has given his consent to act as the scrutinizer, for conducting the Postal Ballot process, in a fair and transparent manner.

Further, this is to confirm that Mr. Glenn Saldanha, Chairman & Managing Director and Mrs. Cherylan Pinto, Executive Director are not debarred from holding the office pursuant to any SEBI order or any such authority respectively.



Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

Brief details of Mr. Glenn Saldanha and Mrs. Cherylann Pinto, in terms of SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015 are enclosed as Annexure I.

You are requested to take the same on record.

Thanking You.

Yours faithfully,

For Glenmark Pharmaceuticals Limited



Harish Kuber

Company Secretary & Compliance Officer



Encl: As above

Tel: 4018 9999 / 4018 9879

Fax: 4018 9986 (Legal & Secretarial Dept.)

Annexure I

Disclosure of events and information pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9th September, 2015

Sr. No.	Particulars	Details	
1.	Name & Designation of Director	Mr. Glenn Saldanha (Chairman & Managing Director)	Mrs. Cherylann Pinto (Executive Director – Corporate Services)
2.	Reason for change	Re-appointment	Re-appointment
3.	Date of appointment & term of appointment	Effective date of re-appointment - From 16th May, 2022 for a further period of 5 years	Effective date of re-appointment - From 16th May, 2022 for a further period of 5 years
4.	Brief Profile	Mr. Glenn Saldanha (DIN 00050607) is a graduate in Pharmacy from the University of Mumbai. He has done Master of Business Administration (MBA) from the Leonard N. Stern School of Business of the New York University. He has wide experience in Pharmaceutical industry, first as a Brand Manager with Eli Lilly (USA) and then with PricewaterhouseCoopers as a Management Consultant. During his leadership, the Company has registered significant growth and has established itself internationally. He served as the Managing Director & Chief Executive Officer of the Company from 2002 to 2012 and from 2012 onwards he's been serving as Chairman & Managing Director.	Mrs. Cherylann Pinto (DIN 00111844) is a graduate in Pharmacy from the University of Mumbai. She has over 32 years of experience in the Pharma Business. She has been instrumental in contributing to the overall growth of the Company. She has been serving as the Executive Director of the Company since 2002.
5.	Disclosure of relationships between directors (in case of appointment of a director)	Mr. Glenn Saldanha is son of Mrs. B.E. Saldanha - Non Executive Director and Brother of Mrs. Cherylann Pinto – Executive Director of the Company.	Mrs. Cherylann Pinto is daughter of Mrs. B.E. Saldanha – Non Executive Director and sister of Mr. Glenn Saldanha – Chairman & Managing Director of the Company.

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

